scPharmaceuticals Q4 EPS $(0.27) Up From $(0.28) YoY
scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.27) per share. This is a 3.57 percent increase over losses of $(0.28) per share from the same period last year.
scPharmaceuticals Q3 EPS $(0.24) Up From $(0.33) YoY
scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.24) per share. This is a 27.27 percent increase over losses of $(0.33) per share from the same period last year.
scPharmaceuticals Inc. Highlights Presentation Of Late-Breaking FREEDOM-HF Study Data At The Heart Failure Society Of America Annual Scientific Meeting 2021
Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX® versus a historical comparator group
Company on
SVB Leerink Initiates Coverage On scPharmaceuticals with Market Perform Rating, Announces Price Target of $6
SVB Leerink analyst Roanna Ruiz initiates coverage on scPharmaceuticals (NASDAQ:SCPH) with a Market Perform rating and announces Price Target of $6.
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
scPharmaceuticals Q2 EPS $(0.26) Up From $(0.36) YoY
scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.26) per share. This is a 27.78 percent increase over losses of $(0.36) per share from the same period last year.
58 Biggest Movers From Yesterday
Gainers
The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share.
